Here, we introduce CRISPR-Enabled Autonomous Transposable Element (CREATE ... CREATE employs a modified L1 mRNA to carry a payload gene, and a Cas9 nickase to facilitate targeted editing by ...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day. ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE ...

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...

Get Instant Summarized Text (Gist) CRISPR nucleases, Cas9 and Cas12, have been engineered to evade immune detection, addressing a key challenge in CRISPR-based therapies. By identifying and ...

Bring up germline editing, and most scientists cringe. The idea behind the notorious CRISPR-baby scandal, editing reproductive cells or embryos tinkers with DNA far beyond just the patient—any changes ...

Then Crispr came along—the elegant enzymatic apparatus that allows delivery of DNA scissors to a specific target in the genome. In December 2023, the FDA approved the first Crispr-based therapy ...

As an efficient gene editing tool, the CRISPR/Cas9 system has been widely employed to investigate and regulate the biosynthetic pathways of active ingredients in medicinal plants. CRISPR technology ...